U.S. markets close in 18 minutes

Agenus Inc. (AGEN)

NasdaqCM - NasdaqCM Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
0.5631+0.0067 (+1.20%)
A partir del 03:42PM EDT. Mercado abierto.

Agenus Inc.

3 Forbes Road
Lexington, MA 02421-7305
United States
781 674 4400
https://www.agenusbio.com

Sector(es)Healthcare
IndustriaBiotechnology
Empleados a tiempo completo389

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Dr. Garo H. Armen Ph.D.Founder, Executive Chairman & CEO1.34MN/D1953
Ms. Christine M. KlaskinVP of Finance, Principal Financial Officer & Principal Accounting Officer407.44kN/D1966
Dr. Steven J. O'Day M.D., Ph.D.Chief Medical Officer970.98kN/D1961
Craig WinterChief Information OfficerN/DN/DN/D
Mr. Zack ArmenHead of Investor RelationsN/DN/DN/D
Ms. Tracy Mazza ClementeChief People OfficerN/DN/DN/D
Mr. Dhan ChandScientific Director & Head of Drug DiscoveryN/DN/DN/D
Mr. Alfred DadsonChief Manufacturing OfficerN/DN/DN/D
Mr. Eric HumesChief Quality OfficerN/DN/DN/D
Dr. Todd Jude Yancey M.D.Member of Advisory Board & Chief Strategic AdvisorN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2022 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Gestión corporativa

La calificación ISS Governance QuickScore de Agenus Inc. a partir del 1 de marzo de 2024 es 6. Las puntuaciones principales son Auditoría: 4; Junta: 6; Derechos del accionista: 8; Compensación: 7.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.